Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer ...

The FDA has given the green light to expand the use of Moderna's vaccine for the treatment of RSV, the virus that causes ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

In a move that has surprised many, vaccine advisers working with independent presidential candidate Robert F. Kennedy Jr. (RFK Jr.) have publicly supported the RSV (respiratory syncytial virus) ...